Twitter LinkedIn
    Wednesday, May 25
    Login
    0 Shopping Cart
    Twitter LinkedIn
    Private Equity InsiderPrivate Equity Insider
    • About Us
    • Digital Events
    • Our Network
      • Reach
      • Sponsors
      • Members
    Private Equity InsiderPrivate Equity Insider
    Home»Deals»Citizens advises Bionix Development Corporation on recapitalisation by Argosy Private Equity
    Deals

    Citizens advises Bionix Development Corporation on recapitalisation by Argosy Private Equity

    February 17, 20212 Mins Read
    LinkedIn Facebook Twitter Email WhatsApp
    Share
    LinkedIn Facebook Twitter Email WhatsApp

    Citizens M&A Advisory served as the exclusive M&A advisor to Bionix Development Corporation on its recapitalisation by Argosy Private Equity.

    Bionix, headquartered in Toledo, Ohio, is a leading developer of innovative healthcare products for single-use ear, nasal and wound care applications, among others. Co-founded in 1984 by Drew Milligan, PhD, and Jim Huttner, MD, PhD, Bionix produces its products in the United States and is trusted by physicians throughout the care continuum for developing premium products that set innovation, quality and performance standards. Argosy’s investment will allow Bionix’s co-founders and management team, led by President and CEO Chris Becker, to accelerate the company’s new product development and other organic and inorganic growth opportunities.

    “We are greatly appreciative of the Citizens M&A Advisory team’s guidance throughout this recapitalisation process, which has provided us with an ideal partner in Argosy for accelerating growth and maintaining Bionix’s proud legacy and culture in Toledo,” says Huttner, who will continue in his role as medical director and vice president of product development.

    “Bionix is an exceptional medical device company,” says Andrew Male, managing director in Citizens’ healthcare M&A practice. “We are excited for our clients to be able to accelerate the Company’s growth initiatives through this partnership with Argosy and further build upon the founders’ 30-year legacy of developing innovative, premium healthcare products.”

    Read more/Source: Private Equity Wire

    Related

    Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.

    Capital deals PE Insider Private Equity
    Share. LinkedIn Facebook Twitter Email WhatsApp

    Related Posts

    KKR-Backed UK Startup Paddle Strikes $200 Million Deal

    May 25, 2022

    KKR closes inaugural Asia Credit Fund at $1.1bn

    May 25, 2022

    Cathay Capital launches new €500m health fund

    May 24, 2022

    Pantheon passes $2.4bn in private debt secondaries as flagship fund closes at $834m

    May 24, 2022

    Comments are closed.

    Other Articles

    Aura Raises $150 Million Series E Led by Warburg Pincus

    June 9, 2021

    Fieldfisher hires new Head of Funds

    May 8, 2021

    Brookfield pips Macquarie in $2.7bn move to buy Australian telecoms group Uniti

    April 14, 2022

    L’Oreal up 1.4% after Nestle’s plans to sell $10 billion worth of shares

    December 8, 2021

    Private Equity Insider LLC
    1212 Avenue of the Americas
    New York City 10036
    USA

    [email protected]

    Twitter LinkedIn
    © 2022 Private Equity Insider LLC. All rights reserved.
    • About
    • Terms of Use
    • Cookie Policy
    • Privacy Policy
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.

    View Cart Checkout Continue Shopping

    Sign In or Register

    Welcome Back!

    Login to your account below.

    Lost password?